Albumin-erythropoietin fusion protein (Tianjin SinoBiotech)

重组人血清白蛋白/促红素融合蛋白（天津溥瀛生物技术）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAlbumin-erythropoietin fusion protein (Tianjin SinoBiotech)
Drug Alias Name注射用重组人血清白蛋白/促红素融合蛋白
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTianjin Puying Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTianjin Linda Biotechnology Co LtdFortunerock (China) LtdTianjin Puying Biotechnology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A